http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022033452-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_465b607edb4c88aeefb4958e154efaec |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
filingDate | 2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_832301597094e556bb9070144a1aaa28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0ec1a7057d9b00ae82a2c9c745d1d79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8267fabb70bfbd8804b2e1f8e89b2703 |
publicationDate | 2022-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2022033452-A1 |
titleOfInvention | Polypeptide derived from cap1 and pharmaceutical composition comprising same as effective ingredient |
abstract | The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, fatty hepatitis, arteriosclerosis, cardiovascular diseases, and heart failure. Exhibiting the effect of suppressing the binding of resistin to CAP1 and inhibiting NF-kB activity, the method of the present invention can be useful for treating inflammatory diseases, cancer, diabetes, fatty hepatitis, arteriosclerosis, cardiovascular diseases, and heart failure which are caused by the activation of resistin and NF-kB. |
priorityDate | 2017-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 385.